Insider Transactions in Q3 2024 at Avidity Biosciences, Inc. (RNA)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 23
2024
|
Teresa Mc Carthy Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
13,153
-16.01%
|
$578,732
$44.0 P/Share
|
|
Sep 23
2024
|
Sarah Boyce President and CEO |
SELL
Open market or private sale
|
Direct |
32,880
-12.29%
|
$1,446,720
$44.0 P/Share
|
|
Sep 23
2024
|
W. Michael Flanagan CSTO |
SELL
Open market or private sale
|
Direct |
25,000
-13.75%
|
$1,075,000
$43.95 P/Share
|
|
Sep 23
2024
|
Michael F Mac Lean Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
11,510
-10.67%
|
$506,440
$44.0 P/Share
|
|
Sep 19
2024
|
Teresa Mc Carthy Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+22.17%
|
-
|
|
Sep 19
2024
|
Sarah Boyce President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+18.16%
|
-
|
|
Sep 19
2024
|
W. Michael Flanagan CSTO |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+21.46%
|
-
|
|
Sep 19
2024
|
Michael F Mac Lean Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+17.95%
|
-
|
|
Sep 19
2024
|
Arthur A Levin Director |
SELL
Open market or private sale
|
Direct |
5,000
-25.21%
|
$225,000
$45.73 P/Share
|
|
Sep 19
2024
|
Arthur A Levin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+20.14%
|
$5,000
$1.24 P/Share
|
|
Sep 11
2024
|
W. Michael Flanagan CSTO |
SELL
Open market or private sale
|
Direct |
111,394
-31.95%
|
$4,455,760
$40.4 P/Share
|
|
Sep 11
2024
|
W. Michael Flanagan CSTO |
BUY
Exercise of conversion of derivative security
|
Direct |
96,500
+27.39%
|
$2,316,000
$24.61 P/Share
|
|
Sep 11
2024
|
Teresa Mc Carthy Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
25,000
-30.42%
|
$1,000,000
$40.4 P/Share
|
|
Sep 11
2024
|
Teresa Mc Carthy Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+23.33%
|
$350,000
$14.22 P/Share
|
|
Sep 06
2024
|
Arthur A Levin Director |
BUY
Bona fide gift
|
Indirect |
22,500
+50.0%
|
-
|
|
Sep 06
2024
|
Arthur A Levin Director |
SELL
Bona fide gift
|
Indirect |
22,500
-14.62%
|
-
|
|
Aug 19
2024
|
Arthur A Levin Director |
SELL
Open market or private sale
|
Direct |
5,000
-25.21%
|
$225,000
$45.19 P/Share
|
|
Aug 19
2024
|
Arthur A Levin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+20.14%
|
$5,000
$1.24 P/Share
|
|
Aug 06
2024
|
Sarah Boyce President and CEO |
SELL
Open market or private sale
|
Direct |
28,000
-12.02%
|
$1,204,000
$43.35 P/Share
|
|
Aug 06
2024
|
Sarah Boyce President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
28,000
+10.73%
|
$28,000
$1.24 P/Share
|
|
Aug 01
2024
|
John B Moriarty Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+50.0%
|
-
|
|
Jul 19
2024
|
Arthur A Levin Director |
SELL
Open market or private sale
|
Direct |
5,000
-25.21%
|
$225,000
$45.01 P/Share
|
|
Jul 19
2024
|
Arthur A Levin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+20.14%
|
$5,000
$1.24 P/Share
|
|
Jul 09
2024
|
Sarah Boyce President and CEO |
SELL
Open market or private sale
|
Direct |
28,000
-12.02%
|
$1,092,000
$39.93 P/Share
|
|
Jul 09
2024
|
Sarah Boyce President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
28,000
+10.73%
|
$28,000
$1.24 P/Share
|